TABLE 1 Response rate outcomes of phase III trials.
From the following article:
Advances in the systemic therapy of malignant pleural mesothelioma
Dean A Fennell, Giovanni Gaudino, Kenneth J O'Byrne, Luciano Mutti and Jan van Meerbeeck
BACK TO ARTICLE| Study type or regimen | Number of studies | Number of patients | Intention to treat response rate % (95% CI) |
|---|---|---|---|
The data were originally published in references 1 and 3. | |||
| Single agent | |||
| Long-term alkylating agents | 7 | 194 | 4.6 (1.8–7.5) |
| Anthracyclines, liposomal anthracyclines or mitoxantrone | 10 | 319 | 6.1 (3.6–8.7) |
| Taxanes | 4 | 111 | 5.1 (1.2–9.1) |
| Vinca alkaloids | 5 | 115 | 3.6 (0.4–6.8) |
| Gemcitabine | 3 | 72 | 6.7 (1.2–12.2) |
| Antimetabolites | 8 | 319 | 9.0 (6.0–11.9) |
| Topoisomerase inhibitors | 4 | 117 | 4.9 (1.0–8.8) |
| Cisplatin | 5 | 108 | 20.0 (12.8–27.2) |
| Carboplatin | 3 | 89 | 10.1 (3.9–16.3) |
| Other experimental agents | 12 | 376 | 4.0 (2.0–5.9) |
| Combination regimens | |||
| Platinum-based | 19 | 790 | 24.9 (22.0–27.9) |
| Cisplatin- but not anthracycline-containing | 20 | 547 | 23.2 (19.7–26.8) |
| Anthracycline- and nonplatinum-based | 8 | 213 | 11.3 (7.0–15.5) |
| Cisplatin- and anthracycline-containing | 6 | 151 | 28.5 (21.3–35.7) |
| Nonplatinum- and nonanthracycline-based | 54 | 409 | 11.6 (10.0–13.3) |